A randomized, double-blind, placebo-controlled evaluation of the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of oral BCX10013 in healthy participants
Latest Information Update: 17 Jan 2025
Price :
$35 *
At a glance
- Drugs BCX-10013 (Primary)
- Indications Immunological disorders; Paroxysmal nocturnal haemoglobinuria
- Focus Adverse reactions; First in man
- 17 Jan 2025 New trial record